Khandan Keyomarsi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5000283/publications.pdf

Version: 2024-02-01

153 papers	14,303 citations	53660 45 h-index	19136 118 g-index
156 all docs	156 docs citations	156 times ranked	15666 citing authors

#	Article	IF	Citations
1	Palbociclib plus endocrine therapy significantly enhances overall survival of <scp>HR</scp>+/<scp>HER2</scp>â˜ metastatic breast cancer patients compared to endocrine therapy alone in the secondâ€line setting: A large institutional study. International Journal of Cancer, 2022, 150, 2025-2037.	2.3	16
2	Abstract P2-05-02: Low molecular weight cyclin E facilitate replication stress tolerance in breast cancer development. Cancer Research, 2022, 82, P2-05-02-P2-05-02.	0.4	0
3	PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers. Expert Opinion on Investigational Drugs, 2022, 31, 607-631.	1.9	20
4	CHD1 Promotes Sensitivity to Aurora Kinase Inhibitors by Suppressing Interaction of AURKA with Its Coactivator TPX2. Cancer Research, 2022, 82, 3088-3101.	0.4	2
5	Cytoplasmic Cyclin E Expression Predicts for Response to Neoadjuvant Chemotherapy in Breast Cancer. Annals of Surgery, 2021, 274, e150-e159.	2.1	5
6	Targeting Replicative Stress and DNA Repair by Combining PARP and Wee1 Kinase Inhibitors Is Synergistic in Triple Negative Breast Cancers with Cyclin E or BRCA1 Alteration. Cancers, 2021, 13, 1656.	1.7	16
7	LMW cyclin E and its novel catalytic partner CDK5 are therapeutic targets and prognostic biomarkers in salivary gland cancers. Oncogenesis, 2021, 10, 40.	2.1	2
8	Phase I safety and efficacy study of autophagy inhibition with hydroxychloroquine to augment the antiproliferative and biological effects of preoperative palbociclib plus letrozole for estrogen receptor-positive, HER2-negative metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2021, 39, 1067-1067.	0.8	1
9	Selective CDK4/6 Inhibitors: Biologic Outcomes, Determinants of Sensitivity, Mechanisms of Resistance, Combinatorial Approaches, and Pharmacodynamic Biomarkers. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, 115-126.	1.8	16
10	Cytoplasmic Cyclin E Is an Independent Marker of Aggressive Tumor Biology and Breast Cancer-Specific Mortality in Women over 70 Years of Age. Cancers, 2020, 12, 712.	1.7	3
11	Specific, reversible G1 arrest by UCN-01 in vivo provides cytostatic protection of normal cells against cytotoxic chemotherapy in breast cancer. British Journal of Cancer, 2020, 122, 812-822.	2.9	11
12	Abstract PD2-05: Differential mechanisms of acquired resistance to abemaciclib versus palbociclib reveal novel therapeutic strategies for CDK4/6 therapy-resistant breast cancers. Cancer Research, 2020, 80, PD2-05-PD2-05.	0.4	4
13	Abstract P6-04-12: STAT3 as a therapeutic target in estrogen receptor positive breast cancer patients refractory to CDK4/6 inhibition. , 2020, , .		0
14	Abstract P3-10-02: Neutrophil elastase as a therapeutic target to inhibit metastasis in breast cancer. , 2020, , .		0
15	Abstract P2-05-04: Low molecular weight cyclin E facilitates replication stress tolerance in breast cancer development. , 2020, , .		1
16	Abstract P4-06-03: Assessment of intratumoral heterogeneity in early stage estrogen receptor (ER) positive breast cancer. , 2020, , .		0
17	Abstract P6-03-09: Role of IL-6 in promoting endocrine therapy and palbociclib resistance estrogen receptor positive breast cancer cells. , 2020, , .		0
18	Toxicity of Radiation Therapy Given Concomitantly with Palbociclib for Metastatic Breast Carcinoma. International Journal of Radiation Oncology Biology Physics, 2019, 105, E60.	0.4	1

#	Article	IF	Citations
19	Arthur B. Pardee: In Memoriam (1921â€“2019). Cancer Research, 2019, 79, 2089-2090.	0.4	0
20	Combined Inhibition of STAT3 and DNA Repair in Palbociclib-Resistant ER-Positive Breast Cancer. Clinical Cancer Research, 2019, 25, 3996-4013.	3.2	77
21	Cytoplasmic cyclin E independently predicts recurrence in older patients with primary breast cancer.. Journal of Clinical Oncology, 2019, 37, 3128-3128.	0.8	0
22	Abstract 323: Combined inhibition of STAT-3 & DNA repair in palbociclib resistant breast cancer. , 2019, , .		0
23	Enhancer transcription reveals subtype-specific gene expression programs controlling breast cancer pathogenesis. Genome Research, 2018, 28, 159-170.	2.4	137
24	Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer. Cancer Research, 2018, 78, 742-757.	0.4	98
25	Inhibiting CDK in Cancer Therapy: Current Evidence and Future Directions. Targeted Oncology, 2018, 13, 21-38.	1.7	78
26	Low-Molecular-Weight Cyclin E in Human Cancer: Cellular Consequences and Opportunities for Targeted Therapies. Cancer Research, 2018, 78, 5481-5491.	0.4	39
27	Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase Inhibition. Clinical Cancer Research, 2018, 24, 6594-6610.	3.2	70
28	Histone modification profiling in breast cancer cell lines highlights commonalities and differences among subtypes. BMC Genomics, 2018, 19, 150.	1.2	62
29	Strategic development of AZD1775, a Wee1 kinase inhibitor, for cancer therapy. Expert Opinion on Investigational Drugs, 2018, 27, 741-751.	1.9	43
30	Leveraging MYC as a therapeutic treatment option for TNBC. Oncoscience, 2018, 5, 137-139.	0.9	2
31	Abstract 1843: Combination therapy targeting Rb/Wee1 kinase pathways for rhabdomyosarcoma treatment. , 2018, , .		0
32	CDK4/6 Inhibitors Sensitize Rb-positive Sarcoma Cells to Wee1 Kinase Inhibition through Reversible Cell-Cycle Arrest. Molecular Cancer Therapeutics, 2017, 16, 1751-1764.	1.9	39
33	Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer. Clinical Cancer Research, 2017, 23, 7288-7300.	3.2	29
34	CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers. Nature Communications, 2017, 8, 15916.	5.8	214
35	AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple Cancers. Molecular Cancer Research, 2017, 15, 45-58.	1.5	73
36	Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer. Clinical Cancer Research, 2017, 23, 2991-3002.	3.2	46

#	Article	IF	Citations
37	Rapid Breast Cancer Disease Progression Following Cyclin Dependent Kinase 4 and 6 Inhibitor Discontinuation. Journal of Cancer, 2017, 8, 2004-2009.	1.2	14
38	Abstract 2060: Characterizing acquired resistance to palbociclib in breast cancer. Cancer Research, 2017, 77, 2060-2060.	0.4	3
39	Cyclin E overexpression as a biomarker for combination treatment strategies in inflammatory breast cancer. Oncotarget, 2017, 8, 14897-14911.	0.8	35
40	Relationships of cyclin E with clinical outcome and biomarkers in older women with early operable primary breast cancer.. Journal of Clinical Oncology, 2017, 35, e12031-e12031.	0.8	1
41	Abstract 2338: CDK4/6 and autophagy inhibitors synergize to induce senescence in cancers with an intact G1/S checkpoint. , 2017, , .		0
42	Abstract A15: Downregulation of c-myc is synthetic lethal with PARP inhibitors in high MYC cancers independent of BRCA status. , 2017, , .		0
43	Targeting the Cell Cycle in Breast Cancer. Breast Diseases, 2016, 27, 256-260.	0.0	0
44	Estrogen receptor alpha is cell cycle-regulated and regulates the cell cycle in a ligand-dependent fashion. Cell Cycle, 2016, 15, 1579-1590.	1.3	31
45	Cyclin E Associates with the Lipogenic Enzyme ATP-Citrate Lyase to Enable Malignant Growth of Breast Cancer Cells. Cancer Research, 2016, 76, 2406-2418.	0.4	64
46	Cytoplasmic Cyclin E and Phosphoâ€“Cyclin-Dependent Kinase 2 Are Biomarkers of Aggressive Breast Cancer. American Journal of Pathology, 2016, 186, 1900-1912.	1.9	42
47	PAF-Wnt signaling-induced cell plasticity is required for maintenance of breast cancer cell stemness. Nature Communications, 2016, 7, 10633.	5.8	63
48	Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast Cancer. Molecular Cancer Therapeutics, 2016, 15, 593-607.	1.9	54
49	PKCiota promotes ovarian tumor progression through deregulation of cyclin E. Oncogene, 2016, 35, 2428-2440.	2.6	17
50	Abstract PR06: Analysis of enhancer transcription reveals novel gene regulatory networks in breast cancer. , 2016, , .		0
51	Abstract 2989: An Intact G1/S checkpoint determines response to CDK4/6 inhibitor in breast cancer. , 2016, , .		0
52	A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer. Investigational New Drugs, 2015, 33, 890-894.	1.2	58
53	How will we recruit, train, and retain physicians and scientists to conduct translational cancer research?. Cancer, 2015, 121, 806-816.	2.0	13
54	The serine protease inhibitor elafin maintains normal growth control by opposing the mitogenic effects of neutrophil elastase. Oncogene, 2015, 34, 3556-3567.	2.6	29

#	Article	IF	Citations
55	Abstract 1783: Pharmacological inhibition of CDK4/6 induces G1 arrest, autophagy and senescence in ER+ breast cancer. , 2015, , .		1
56	Abstract P6-03-09: Targeting the c-myc/E2F1 pathway in TNBC promotes a DNA damage dependent synthetic lethality. , 2015, , .		0
57	Abstract P5-05-05: Low molecular weight cyclin E regulates response to aromatase inhibitors in post-menopausal breast cancer patients. , 2015, , .		0
58	Abstract P5-08-02: Inhibition of CDK4/6 induces senescence and autophagy in ER positive breast cancers. , 2015, , .		0
59	Abstract 3772: Cyclin E as a prognostic marker and predictor of response to neoadjuvant chemotherapy and adjuvant hormonal therapy in patients with stage II-III breast cancer. , 2015, , .		0
60	Abstract 3091: Targeting low molecular weight (LMW) cyclin E-Cdk2 pathway for the prevention of breast cancer. , 2015, , .		0
61	Abstract 3579: Identification of biomarkers of AXL-mediated drug resistance in head and neck squamous cell carcinoma. , 2015, , .		0
62	Abstract 1422: Neutrophil Elastase plays a key role in epithelial-mesenchymal transition and metastasis in triple-negative breast cancers. , 2015, , .		0
63	Abstract B27: CDK inhibition impairs homologous recombination and induces PARP inhibitor sensitivity via loss of c-myc expression in TNBC. , 2015, , .		1
64	Indole-3-carbinol and its N-alkoxy derivatives preferentially target ERÎ±-positive breast cancer cells. Cell Cycle, 2014, 13, 2587-2599.	1.3	38
65	Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence. Breast Cancer Research, 2014, 16, 3417.	2.2	21
66	2â€²-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. Nature Communications, 2014, 5, 3459.	5.8	103
67	Exploiting Cell Cycle Pathways in Cancer Therapy: New (and Old) Targets and Potential Strategies. Cancer Drug Discovery and Development, 2014, , 337-372.	0.2	1
68	A phase 1 study of dinaciclib (SCH 727965) in combination with epirubicinin patients with metastatic triple-negative breast cancer.. Journal of Clinical Oncology, 2014, 32, 163-163.	0.8	2
69	Abstract 1327: Targeting the RB-pathway in sarcoma: Utility of CDK4/6 inhibitors. , 2014, , .		0
70	Elafin, an inhibitor of elastase, is a prognostic indicator in breast cancer. Breast Cancer Research, 2013, 15, R3.	2.2	40
71	EVI1 splice variants modulate functional responses in ovarian cancer cells. Molecular Oncology, 2013, 7, 647-668.	2.1	38
72	Staurosporine is chemoprotective by inducing G 1 arrest in a Chk1- and pRb-dependent manner. Carcinogenesis, 2013, 34, 2244-2252.	1.3	10

#	Article	IF	Citations
73	Hbo1 Is a Cyclin E/CDK2 Substrate That Enriches Breast Cancer Stem-like Cells. Cancer Research, 2013, 73, 5556-5568.	0.4	46
74	LMW-E/CDK2 Deregulates Acinar Morphogenesis, Induces Tumorigenesis, and Associates with the Activated b-Raf-ERK1/2-mTOR Pathway in Breast Cancer Patients. PLoS Genetics, 2012, 8, e1002538.	1.5	35
75	Low molecular weight cyclin E is associated with p27-resistant, high-grade, high-stage and invasive bladder cancer. Cell Cycle, 2012, 11, 1468-1476.	1.3	18
76	Targeting low molecular weight cyclin E (LMW-E) in breast cancer. Breast Cancer Research and Treatment, 2012, 132, 575-588.	1.1	35
77	Abstract 2466: Elafin, a serine protease inhibitor, is deregulated during breast cancer progression. , 2012, , .		1
78	Abstract 3283: Conditional Low-molecular-weight (LMW) cyclin E-induced mammary tumorigenesis. , 2012, , .		0
79	Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients. Breast Diseases, 2011, 22, 266-267.	0.0	0
80	MDA-7 results in downregulation of AKT concomitant with apoptosis and cell cycle arrest in breast cancer cells. Cancer Gene Therapy, 2011, 18, 510-519.	2.2	8
81	Semi-high throughput method of measuring proteasome inhibition in vitro and in cultured cells. Cell Biology and Toxicology, 2011, 27, 123-131.	2.4	4
82	Cdk2 is Required for Breast Cancer Mediated by the Low-Molecular-Weight Isoform of Cyclin E. Cancer Research, 2011, 71, 3377-3386.	0.4	55
83	Breaking the cycle: An insight into the role of ERÎ± in eukaryotic cell cycles. Journal of Carcinogenesis, 2011, 10, 25.	2.5	12
84	A novel interaction between HER2/neu and cyclin E in breast cancer. Oncogene, 2010, 29, 3896-3907.	2.6	54
85	Cyclin E Deregulation Impairs Mitotic Progression through Premature Activation of Cdc25C. Cancer Research, 2010, 70, 5085-5095.	0.4	33
86	The Neutrophil Elastase Inhibitor Elafin Triggers Rb-Mediated Growth Arrest and Caspase-Dependent Apoptosis in Breast Cancer. Cancer Research, 2010, 70, 7125-7136.	0.4	26
87	Low Molecular Weight Cyclin E Overexpression Shortens Mitosis, Leading to Chromosome Missegregation and Centrosome Amplification. Cancer Research, 2010, 70, 5074-5084.	0.4	53
88	Low-Molecular-Weight Cyclin E Can Bypass Letrozole-Induced G1 Arrest in Human Breast Cancer Cells and Tumors. Clinical Cancer Research, 2010, 16, 1179-1190.	3.2	47
89	Absence of pRb facilitates E2F1-induced apoptosis in breast cancer cells. Cell Cycle, 2010, 9, 1122-1130.	1.3	19
90	Abstract 3057: The serine protease inhibitor, elafin, exhibits novel tumor suppressor functions in the context of breast cancer. , 2010, , .		0

#	Article	IF	Citations
91	Altered Subcellular Localization of Tumor-Specific Cyclin E Isoforms Affects Cyclin-Dependent Kinase 2 Complex Formation and Proteasomal Regulation. Cancer Research, 2009, 69, 2817-2825.	0.4	39
92	Low molecular weight cyclin E is specific in breast cancer and is associated with mechanisms of tumor progression. Cell Cycle, 2009, 8, 1062-1068.	1.3	45
93	DEAR1 Is a Dominant Regulator of Acinar Morphogenesis and an Independent Predictor of Local Recurrence-Free Survival in Early-Onset Breast Cancer. PLoS Medicine, 2009, 6, e1000068.	3.9	37
94	Integrative Analysis of Cyclin Protein Levels Identifies Cyclin B1 as a Classifier and Predictor of Outcomes in Breast Cancer. Clinical Cancer Research, 2009, 15, 3654-3662.	3.2	121
95	Cyclin E deregulation is an early event in the development of breast cancer. Breast Cancer Research and Treatment, 2009, 115, 651-659.	1.1	32
96	Post-translational modification and stability of low molecular weight cyclin E. Oncogene, 2009, 28, 3167-3176.	2.6	10
97	Biomarkers in Neoadjuvant Trials. Cancer Treatment and Research, 2009, 147, 1-36.	0.2	0
98	A novel MCM-2 fragment with potential biological function in senescence. Cell Cycle, 2008, 7, 3479-3480.	1.3	0
99	Autophagy: A Novel Mechanism of Synergistic Cytotoxicity between Doxorubicin and Roscovitine in a Sarcoma Model. Cancer Research, 2008, 68, 7966-7974.	0.4	95
100	Synchronization of the cell cycle using Lovastatin. Cell Cycle, 2008, 7, 2434-2440.	1.3	68
101	Cyclin Eâ€“Associated Kinase Activity Predicts Response to Platinum-Based Chemotherapy. Clinical Cancer Research, 2007, 13, 4800-4806.	3.2	15
102	Overexpression of the Low Molecular Weight Cyclin E in Transgenic Mice Induces Metastatic Mammary Carcinomas through the Disruption of the ARF-p53 Pathway. Cancer Research, 2007, 67, 7212-7222.	0.4	64
103	Differential Regulation of Elafin in Normal and Tumor-Derived Mammary Epithelial Cells Is Mediated by CCAAT/Enhancer Binding Protein Î². Cancer Research, 2007, 67, 11272-11283.	0.4	19
104	The Double-Stranded RNA-Activated Protein Kinase Mediates Radiation Resistance in Mouse Embryo Fibroblasts through Nuclear Factor ÎºB and Akt Activation. Clinical Cancer Research, 2007, 13, 6032-6039.	3.2	26
105	Cell Cycle Deregulation in Breast Cancer: Insurmountable Chemoresistance or Achillesâ€™ Heel?. Advances in Experimental Medicine and Biology, 2007, 608, 52-69.	0.8	5
106	Deregulation of cyclin E meets dysfunction in p53: Closing the escape hatch on breast cancer. Journal of Cellular Physiology, 2006, 209, 686-694.	2.0	23
107	Anti-HER2 Antibody Trastuzumab Inhibits CDK2-Mediated NPAT and Histone H4 Expression via PI3K Pathway. Cell Cycle, 2006, 5, 1654-1661.	1.3	26
108	The Differential Staurosporine-Mediated G1 Arrest in Normal versus Tumor Cells Is Dependent on the Retinoblastoma Protein. Cancer Research, 2006, 66, 9744-9753.	0.4	15

#	Article	IF	Citations
109	Farnesyl and Geranylgeranyl Transferase Inhibitors Induce G1 Arrest by Targeting the Proteasome. Cancer Research, 2006, 66, 1040-1051.	0.4	46
110	Cyclin E as a prognostic and predictive marker in breast cancer. Seminars in Cancer Biology, 2005, 15, 319-326.	4.3	56
111	Clinical outcome of patients with lymph node-negative breast carcinoma who have sentinel lymph node micrometastases detected by immunohistochemistry. Cancer, 2005, 104, 1779-1780.	2.0	0
112	Atypical PKCÂ contributes to poor prognosis through loss of apical-basal polarity and Cyclin E overexpression in ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 12519-12524.	3.3	231
113	The Tumor-specific Hyperactive Forms of Cyclin E Are Resistant to Inhibition by p21 and p27. Journal of Biological Chemistry, 2005, 280, 15148-15157.	1.6	57
114	The low molecular weight cyclin E isoforms augment angiogenesis and metastasis of human melanoma cells in vivo. Cancer Research, 2005, 65, 692-7.	0.4	44
115	Activation of Cyclin-dependent Kinase 2 by Full Length and Low Molecular Weight Forms of Cyclin E in Breast Cancer Cells. Journal of Biological Chemistry, 2004, 279, 12695-12705.	1.6	31
116	Tumor-Specific Low Molecular Weight Forms of Cyclin E Induce Genomic Instability and Resistance to p21, p27, and Antiestrogens in Breast Cancer. Cancer Research, 2004, 64, 3198-3208.	0.4	134
117	Cyclin E deregulation alters the biologic properties of ovarian cancer cells. Oncogene, 2004, 23, 2648-2657.	2.6	58
118	Role of cell cycle in mediating sensitivity to radiotherapy. International Journal of Radiation Oncology Biology Physics, 2004, 59, 928-942.	0.4	870
119	Low-molecular-weight cyclin E: the missing link between biology and clinical outcome. Breast Cancer Research, 2004, 6, 188-91.	2.2	24
120	Cyclin E is a more powerful predictor of breast cancer outcome than proliferation. Nature Medicine, 2003, 9, 152-152.	15.2	25
121	The Low Molecular Weight Isoforms of Cyclin E Deregulate the Cell Cycle of Mammary Epithelial Cells. Cell Cycle, 2003, 2, 459-464.	1.3	36
122	Cyclin E and Its Low Molecular Weight Forms in Human Cancer and as Targets for Cancer Therapy. Cancer Biology and Therapy, 2003, 2, 37-46.	1.5	63
123	Cyclin E in Breast Cancer. New England Journal of Medicine, 2003, 348, 1063-1064.	13.9	3
124	The low molecular weight (LMW) isoforms of cyclin E deregulate the cell cycle of mammary epithelial cells. Cell Cycle, 2003, 2, 461-6.	1.3	19
125	Cyclin E and its low molecular weight forms in human cancer and as targets for cancer therapy. Cancer Biology and Therapy, 2003, 2, S38-47.	1.5	34
126	Selective protection of normal proliferating cells against the toxic effects of chemotherapeutic agents. Progress in Cell Cycle Research, 2003, 5, 527-32.	0.9	17

#	Article	IF	Citations
127	Cyclin E and Survival in Patients with Breast Cancer. New England Journal of Medicine, 2002, 347, 1566-1575.	13.9	522
128	Phosphorylation-Dependent Ubiquitination of Cyclin E by the SCFFbw7 Ubiquitin Ligase. Science, 2001, 294, 173-177.	6.0	718
129	Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53. Oncogene, 2001, 20, 147-155.	2.6	332
130	Tumor-Specific Proteolytic Processing of Cyclin E Generates Hyperactive Lower-Molecular-Weight Forms. Molecular and Cellular Biology, 2001, 21, 6254-6269.	1.1	179
131	Activation of the Estrogen-Signaling Pathway by p21WAF1/CIP1 in Estrogen Receptor-Negative Breast Cancer Cells. Journal of the National Cancer Institute, 2000, 92, 1403-1413.	3.0	36
132	Differential mRNA expression of the human DNA methyltransferases (DNMTs) 1, 3a and 3b during the G0/G1 to S phase transition in normal and tumor cells. Nucleic Acids Research, 2000, 28, 2108-2113.	6.5	170
133	Novel splice variants of cyclin E with altered substrate specificity. Nucleic Acids Research, 2000, 28, 101e-101.	6.5	48
134	Expression of an estrogen receptor alpha variant protein in cell lines and tumors. Molecular and Cellular Endocrinology, 2000, 162, 167-180.	1.6	18
135	Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 7797-7802.	3.3	346
136	UCN-01-mediated G1 arrest in normal but not tumor breast cells is pRb-dependent and p53-independent. Oncogene, 1999, 18, 5691-5702.	2.6	62
137	The Biphasic Induction of p21 and p27 in Breast Cancer Cells by Modulators of cAMP Is Posttranscriptionally Regulated and Independent of the PKA Pathway. Experimental Cell Research, 1999, 252, 211-223.	1.2	19
138	Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53. Oncogene, 1998, 17, 2393-2402.	2.6	177
139	Molecular Cloning, Characterization, and Regulation of the Human Mitochondrial Serine Hydroxymethyltransferase Gene. Journal of Biological Chemistry, 1997, 272, 1842-1848.	1.6	117
140	The role of cyclin E in cell proliferation, development and cancer. , 1997, 3, 171-191.		107
141	Cyclin E, a redundant cyclin in breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 15215-15220.	3.3	114
142	Synchronization of mammalian cells by Lovastatin. Cytotechnology, 1996, 18, 109-114.	0.7	4
143	Cyclin E â€" a better prognostic marker for breast cancer than cyclin D?. Nature Medicine, 1996, 2, 254-254.	15.2	29
144	Synthesis and Biological Activity of N.omega.-Hemiphthaloyl-.alpha.,.omega.-diaminoalkanoic Acid Analogs of Aminopterin and 3',5-Dichloroaminopterin. Journal of Medicinal Chemistry, 1994, 37, 2167-2174.	2.9	27

#	Article	IF	Citations
145	The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell, 1993, 75, 805-816.	13.5	5,487
146	Redundant cyclin overexpression and gene amplification in breast cancer cells.. Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 1112-1116.	3.3	481
147	Transcriptional downregulation of gap-junction proteins blocks junctional communication in human mammary tumor cell lines.. Journal of Cell Biology, 1992, 118, 1213-1221.	2.3	226
148	Down-regulation of a member of the S100 gene family in mammary carcinoma cells and reexpression by azadeoxycytidine treatment.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 2504-2508.	3.3	142
149	Modification of cell proliferation with inhibitors. Current Opinion in Cell Biology, 1992, 4, 186-191.	2.6	24
150	Progression through the Cell Cycle: An Overview. The American Review of Respiratory Disease, 1990, 142, S3-S6.	2.9	6
151	An efficient deletion mutant packaging system for defective herpes simplex virus vectors: potential applications to human gene therapy and neuronal physiology.. Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 8950-8954.	3.3	263
152	[47] Preparation of (6S)-5-formyltetrahydrofolate labeled at high specific activity with 14C and 3H. Methods in Enzymology, 1986, 122, 309-312.	0.4	9
153	Understanding the Biology of Cancer. , 0, , 101-122.		0